An Anti-Inflammatory Sterol Decreases Obesity-Related Inflammation-Induced Insulin Resistance and Metabolic Dysregulation

Table 3

HE3286-0401 significant correlates of HbA1c and Hb changes.

Group	Dependent	Independent	Test	HE3286				Placebo
				n	r	95% CI	P	n	r	95% CI	P
Cohort 1	ΔHbA1c^a	MCP-1	Spearman	34	−0.42	−0.67 to −0.08	0.01				>0.10
		ΔHOMA2 %B	Spearman	34	−0.43	−0.68 to 0.10	0.01				>0.10
		ΔGlucose	Spearman	34	0.45	0.11 to 0.69	0.009				>0.10
		ΔWeight	Spearman	34	0.45	0.13 to 0.69	0.007				>0.10
		ΔHb	Pearson	34	0.36	0.03 to 0.62	0.03				>0.10
	ΔHbA1c	TNF𝛼	Spearman				>0.10	34	−0.48	−0.71 to −0.16	0.004
		ΔGlucose	Spearman				>0.10	38	0.65	0.41 to 0.81	<0.0001
		ΔTNF𝛼	Spearman				>0.10	32	0.40	0.05 to 0.66	0.02
	HbA1c CV	TNF𝛼	Pearson				>0.10	34	0.50	0.19 to 0.72	0.002
Cohort 2	ΔHbA1c	BMI	Spearman	25	−0.41	−0.70 to −0.008	0.04				>0.10
		ΔHOMA2 %B	Pearson	25	−0.50	−0.75 to −0.13	0.02				>0.10
		ΔGlucose	Pearson	25	0.61	0.29 to 0.81	0.001				>0.10
	HbA1c CV	Hb CV	Pearson				>0.10	28	0.44	0.08 to 0.70	0.02
		ΔMCP-1	Pearson				>0.10	20^b	0.44	0.002 to 0.74	0.0495
		ΔWeight	Pearson				>0.10	28	−0.43	−0.69 to −0.07	0.02
	Hb CV	MCP-1	Spearman				>0.10	20	0.38	0.03 to 0.70	0.04
Cohort 2; BMI > 31	ΔnHbA1c	MCP-1	Spearman Exact	10^b	−0.68	—^c	0.03				>0.10
		ΔMCP-1	Spearman Exact	9^b	0.77	—	0.002				>0.10

^aΔ: change in; CV: coefficient of variation; HbA1c: hemoglobin A1c; Hb: hemoglobin; MCP-1: monocyte chemoattractant protein-1; HOMA2 %B: homeostatic model assessment of pancreatic beta cell function; TNF𝛼: tumor necrosis factor alpha; BMI: body mass index; nHbA1c: HbA1c normalized to day 84 hemoglobin mass (see Section 2 for details). ^bMCP-1 data unavailable on a portion of participants. ^cSpearman Exact test has no confidence interval.